Lynparza 150 MG (Olaparib)

Basic Product Information of Lynparza 150 MG (Olaparib)

How Lynparza 150 MG (Olaparib) Works: PARP1/2 Inhibition, Synthetic Lethality, and PARP Trapping in BRCA-Mutated and HRD-Positive Tumors

Olaparib, the active ingredient in Lynparza 150 MG, is the world’s first approved PARP (Poly ADP-ribose polymerase) inhibitor a pharmacological class that exploits a fundamental genetic vulnerability in tumor cells harboring defects in homologous recombination (HR)-mediated DNA repair, most commonly caused by germline or somatic mutations in the BRCA1 or BRCA2 tumor suppressor genes. PARP1 and PARP2 are nuclear enzymes that detect and repair DNA single-strand breaks (SSBs) through the base excision repair (BER) pathway; they function by synthesizing poly ADP-ribose chains on themselves and target proteins at the site of DNA damage, recruiting downstream BER components to restore DNA strand continuity.

In normal cells, inhibition of PARP-mediated SSB repair creates DNA double-strand breaks (DSBs) during replication, but these DSBs are efficiently corrected by the backup homologous recombination (HR) repair pathway relying on BRCA1 and BRCA2 as essential mediators of RAD51-driven DSB repair. In tumor cells where BRCA1 or BRCA2 function is lost through germline mutation, somatic mutation, or promoter methylation, the HR pathway is non-functional, and the PARP-inhibitor-induced DSBs cannot be repaired triggering synthetic lethality: the simultaneous functional loss of both PARP-mediated BER and HR-mediated DSB repair, which is lethal to the tumor cell but not to normal cells that retain functional HR. This mechanism of synthetic lethality defines olaparib’s selective antitumor activity and mechanistically distinguishes PARP inhibition from conventional cytotoxic chemotherapy.

Oncology specialists and procurement teams can review the complete range of oncology medicines available at Mediaid Pharmacy.

Olaparib’s mechanism of action operates through two complementary and synergistic molecular mechanisms at the 300 mg BID maintenance dose delivered by two Lynparza 150 MG tablets. The first mechanism is PARP catalytic inhibition: olaparib binds the NAD⁺ (nicotinamide adenine dinucleotide)-binding catalytic domain of PARP1 and PARP2 with high affinity and specificity (IC₅₀ approximately 1–5 nM for PARP1; approximately 0.6–2 nM for PARP2), blocking the enzymatic synthesis of poly ADP-ribose (PAR) chains on target proteins and preventing the initiation of BER at SSB sites.

The second and mechanistically more potent mechanism is PARP trapping: olaparib stabilizes the PARP1–DNA complex at sites of DNA damage, preventing the normal release of PARP1 from the DNA after auto-PARylation. These PARP1–DNA trapped complexes are structurally distinct from simple unrepaired SSBs; they constitute a far more cytotoxic DNA lesion type that physically blocks the replication fork machinery during S-phase, generating one-ended DSBs that are irreparable in the absence of functional HR. The potency of PARP trapping by olaparib substantially greater than that of catalytic inhibition alone explains why olaparib achieves clinical antitumor activity at doses that do not cause severe myelosuppression in all patients.

HRD (homologous recombination deficiency) extends beyond BRCA1/2 mutations to include somatic mutations or promoter methylation of other HR pathway genes (RAD51C, RAD51D, PALB2, BRIP1, CDK12), collectively defining a broader population of patients with HRD-positive tumors who may benefit from olaparib treatment beyond those with confirmed BRCAm. Healthcare providers sourcing Lynparza 150 MG and companion targeted oncology agents can browse the complete ovarian cancer medicines portfolio at Mediaid Pharmacy for consolidated worldwide procurement.

Lynparza 150 MG delivers the 150 mg tablet unit dose of olaparib two tablets (300 mg total) taken orally twice daily which is the approved standard dose for all indications, providing continuous 24-hour PARP inhibition through its oral bioavailability profile. The pharmacokinetic characteristics of olaparib at 300 mg BID: median Tmax approximately 1.5 hours, Cmax approximately 6 μg/mL, AUC at steady state approximately 34 μg·h/mL, plasma protein binding approximately 82%, volume of distribution approximately 167 L, terminal half-life (t½) approximately 11.9 hours supporting the twice-daily oral dosing schedule and confirming that steady-state PARP inhibitory drug concentrations are maintained continuously throughout the 12-hour dosing interval.

Olaparib is primarily metabolized by CYP3A4 (responsible for approximately 70% of clearance), with no active circulating metabolites contributing meaningfully to systemic pharmacological activity. Food does not affect olaparib bioavailability in a clinically meaningful way, though the prescribing information recommends administration with food to reduce nausea frequency. No dose adjustment is required for mild hepatic impairment (Child-Pugh A); data for moderate hepatic impairment are limited and require caution; olaparib is not recommended for severe hepatic impairment. Mild renal impairment (creatinine clearance 51–80 mL/min) does not require dose adjustment; for moderate renal impairment (CrCl 31–50 mL/min), the recommended dose is reduced to 200 mg BID (not 300 mg BID). Oncology centers sourcing Lynparza 150 MG in China-market packaging can explore the broader prostate cancer medicines collection at Mediaid Pharmacy for consolidated procurement and worldwide shipping.

The cross-tumor clinical activity of olaparib reflects the genomic ubiquity of BRCA mutations and HRD across solid tumor histologies. In the landmark SOLO-1 Phase 3 trial (n=391; first-line maintenance in BRCAm advanced ovarian cancer after complete or partial response to platinum-based chemotherapy), olaparib 300 mg BID produced a 7-year progression-free survival (PFS) rate of 46% versus 5% with placebo (HR 0.33; 95% CI 0.25–0.43) and a confirmed overall survival benefit at the 7-year data cut (HR 0.55; 95% CI 0.40–0.76; p=0.0004), making SOLO-1 one of the first maintenance therapy trials in solid tumor oncology to demonstrate a statistically significant OS benefit.

In the adjuvant breast cancer setting, the OlympiA Phase 3 trial (n=1,836; germline BRCAm HER2-negative early high-risk breast cancer) produced a 4-year iDFS of 82.7% versus 75.4% with placebo (HR 0.42; p<0.001) an absolute 7.3 percentage point improvement in invasive disease-free survival at 4 years alongside a confirmed OS benefit (HR 0.68; 95% CI 0.47–0.97; p=0.009), the first PARP inhibitor to demonstrate overall survival benefit in early-stage breast cancer. In metastatic castration-resistant prostate cancer, the PROfound Phase 3 trial (n=387; BRCAm cohort) produced a median radiographic progression-free survival (rPFS) of 7.4 versus 3.6 months with enzalutamide or abiraterone (HR 0.34; p<0.001), with an ORR of 33.3% versus 2.3% establishing olaparib as the standard-of-care targeted therapy in BRCAm mCRPC after second-generation androgen receptor inhibitor therapy.

Approved Indications of Lynparza 150 MG (Olaparib) Reference Label and China NMPA-Registered Indications

Olaparib, the active ingredient in Lynparza 150 MG, carries regulatory approvals across four tumor types in multiple clinical settings ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer each requiring prior confirmation of the relevant BRCA mutation status or HRD status by a validated companion diagnostic test on tumor tissue (next-generation sequencing, allele-specific PCR, or FISH) or germline blood testing. The standard dose of 300 mg BID (two 150 mg tablets twice daily) applies across all approved indications, with dose reductions specified for tolerability or drug interactions. The China NMPA-approved label for Lynparza (利普卓) covers these settings; prescribers should confirm the currently registered China NMPA indications and any specific Chinese population data requirements on the Lynparza China product label before initiating treatment, as labeling details may differ from the global FDA/EMA reference prescribing information.

Key Clinical Benefits of Lynparza 150 MG (Olaparib)

Drug Interactions and Important Safety Information for Lynparza 150 MG (Olaparib)

The most clinically significant drug interactions for olaparib involve CYP3A4 inhibitors and inducers, P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) substrates, myelosuppressive agents with overlapping hematologic toxicity profiles, and OATP1B1/1B3 transporter substrates. Olaparib is primarily metabolized by CYP3A4 responsible for approximately 70% of total olaparib clearance making olaparib’s systemic exposure highly sensitive to both inhibition and induction of CYP3A4 by concomitant medications. The pharmacokinetic interactions of CYP3A4 modulators with olaparib at the standard 300 mg BID dose are among the most clinically consequential in oral oncology practice, as exposures outside the therapeutic range increase either the risk of serious adverse events (over-exposure from inhibition) or the risk of treatment failure (under-exposure from induction). Olaparib itself inhibits BCRP, OATP1B1, and OCT1 transporters at clinically relevant concentrations meaning olaparib can increase the systemic exposure of co-administered substrates of these transporters. Oncology centers sourcing Lynparza 150 MG and companion oncology medicines can browse the complete breast cancer medicines range at Mediaid Pharmacy.

Strong CYP3A4 inhibitors are the highest-priority interaction class for olaparib at the 300 mg BID dose. Concomitant administration of itraconazole the prototypical strong CYP3A4 inhibitor increases olaparib AUC by approximately 2.7-fold at steady state, raising olaparib plasma exposure to levels associated with increased myelosuppression, nausea, and hepatotoxicity risk. Other strong CYP3A4 inhibitors contraindicated or requiring dose reduction with olaparib include: antifungals (voriconazole, posaconazole, ketoconazole); HIV protease inhibitors (ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, cobicistat-boosted regimens); antibiotics (clarithromycin, telithromycin); and hepatitis C NS5A inhibitors (grazoprevir/elbasvir, which are increasingly prescribed in patients with cancer and concurrent HCV infection). If a strong CYP3A4 inhibitor cannot be avoided during olaparib 300 mg BID therapy, the olaparib dose must be reduced to 100 mg BID (not 150 mg BID) to compensate for increased exposure; this dose reduction requires careful pharmacokinetic judgment and must be prescribed by the treating oncologist.

Moderate CYP3A4 inhibitors (fluconazole, diltiazem, erythromycin, ciclosporin, aprepitant, amiodarone) increase olaparib AUC by approximately 50–100%, and require an olaparib dose reduction to 150 mg BID (one tablet twice daily) when concomitant use cannot be avoided. Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s Wort, enzalutamide itself which induces CYP3A4 at the enzalutamide doses used in prostate cancer treatment) reduce olaparib AUC by up to 87% to sub-therapeutic plasma concentrations that are likely to eliminate clinical efficacy. Concomitant use of strong CYP3A4 inducers with olaparib must be avoided entirely; the clinical oncologist and pharmacist must review every patient’s medication list specifically for CYP3A4 inducers including anticonvulsant co-medications in patients with CNS metastases and herbal supplements including St. John’s Wort before initiating olaparib and at each follow-up visit. For AstraZeneca-branded companion oncology medicines available at Mediaid Pharmacy, explore the AstraZeneca oncology medicines portfolio.

Myelosuppressive agents represent the most clinically consequential pharmacodynamic interaction class for olaparib. Olaparib’s dose-limiting hematologic toxicity anemia (all grades approximately 43%; Grade 3/4 approximately 16–21%), neutropenia (all grades approximately 18%; Grade 3/4 approximately 7–8%), and thrombocytopenia (all grades approximately 10%) can be substantially amplified by concomitant use of other myelosuppressive agents including cytotoxic chemotherapy (platinum agents, taxanes, gemcitabine, etoposide), androgen deprivation therapy (ADT) which independently suppresses erythropoiesis in patients with prostate cancer and immunosuppressants. Co-administration of olaparib with chemotherapy outside specifically approved combination regimens (olaparib plus bevacizumab in the PAOLA-1 regimen; olaparib plus abiraterone in the PROPEL regimen) is not supported by Phase 3 data and should only be undertaken within a clinical trial protocol.

Olaparib as a BCRP and OATP1B1 inhibitor: olaparib inhibits BCRP at clinically relevant concentrations increasing systemic exposure of BCRP substrates including rosuvastatin (AUC approximately doubled), sulfasalazine, and topotecan when co-administered; statin doses should be reviewed and potentially reduced when initiating olaparib in patients on concurrent statin therapy. Olaparib inhibits OATP1B1 potentially increasing exposure of OATP1B1 substrates including pravastatin, repaglinide, and several antidiabetic agents.

Warfarin and vitamin K antagonists: olaparib may reduce the systemic exposure of warfarin by approximately 23% via an uncertain mechanism; INR monitoring should be intensified when olaparib is initiated, dose-adjusted, or discontinued in patients on anticoagulation with vitamin K antagonists. All patients must disclose their complete medication list including prescription, over-the-counter, traditional Chinese medicine, and herbal preparations to their treating oncologist and clinical pharmacist before initiating Lynparza 150 MG and at every follow-up visit, as the CYP3A4-mediated PK interactions and transporter-mediated pharmacodynamic interactions create multiple clinically significant interaction risks that require proactive management. For the complete olaparib PARP inhibitor tablet range available at Mediaid Pharmacy with worldwide shipping, visit the oncology medicines collection.

Side Effects and Precautions of Lynparza 150 MG (Olaparib)

Who Should Use Lynparza 150 MG (Olaparib)?

Lynparza 150 MG (Olaparib) is indicated for adult patients across four distinct tumor types and multiple clinical settings, each requiring prior molecular confirmation of BRCA mutation status or HRD status by a validated companion diagnostic.

Patient group 1 Ovarian cancer: Adults with advanced (Stage III/IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring germline or somatic BRCA1/2 mutations in complete or partial response to first-line platinum-based chemotherapy receive olaparib 300 mg BID as first-line maintenance treatment the setting in which SOLO-1 established a 7-year OS benefit. Adults with HRD-positive advanced ovarian cancer in complete or partial response to first-line platinum-based chemotherapy plus bevacizumab receive olaparib 300 mg BID combined with bevacizumab as first-line maintenance (PAOLA-1 regimen). Adults with BRCAm platinum-sensitive relapsed ovarian cancer in response to platinum re-challenge receive olaparib 300 mg BID as maintenance treatment (SOLO-2 regimen).

Patient group 2 Breast cancer: Adults with germline BRCA1/2 mutations, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-negative) early high-risk breast cancer who have completed neoadjuvant or adjuvant chemotherapy receive olaparib 300 mg BID for 1 year as adjuvant treatment the OlympiA indication demonstrating iDFS HR 0.42 and OS benefit. Adults with germline BRCA1/2 mutations, HER2-negative locally advanced or metastatic breast cancer receive olaparib 300 mg BID after prior chemotherapy (OlympiAD indication).

Patient group 3 Prostate cancer: Adults with germline or somatic BRCAm mCRPC who have progressed on or after enzalutamide or abiraterone receive olaparib 300 mg BID (PROfound indication; BRCA1/2 cohort rPFS HR 0.34 and OS HR 0.69). Adults with mCRPC without prior systemic therapy receive olaparib 300 mg BID plus abiraterone 1,000 mg daily plus prednisone 5 mg twice daily (PROPEL first-line mCRPC combination regimen; overall rPFS HR 0.66).

Patient group 4 Pancreatic cancer: Adults with germline BRCAm metastatic pancreatic adenocarcinoma who have not progressed after at least 16 weeks of first-line platinum-based chemotherapy receive olaparib 300 mg BID as maintenance treatment (POLO indication; median PFS 7.4 versus 3.8 months; HR 0.53; p=0.004).

Contraindications include: confirmed hypersensitivity to olaparib or any tablet excipient; active MDS or confirmed prior MDS; pregnancy; active breastfeeding; and concomitant use of strong CYP3A4 inducers (unless clinically unavoidable after oncologist review). For procurement of Lynparza 150 MG Olaparib in China-market packaging (利普卓) alongside AstraZeneca companion oncology medicines, visit the Mediaid Pharmacy AstraZeneca medicines portfolio and the complete ovarian cancer medicines collection for worldwide delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Lynparza 150 MG (Olaparib)

Mediaid Pharmacy is a Dhaka-based supplier of specialty oncology, targeted therapy, and original molecule medicines with worldwide shipping to patients, oncology clinics, hospitals, cancer treatment centers, and pharmaceutical distributors across all regions. Lynparza 150 MG Olaparib, manufactured by AstraZeneca in China-market packaging (利普卓), is available as 150 mg film-coated tablets at the standard 300 mg BID dosing schedule (two tablets taken twice daily) requiring no refrigeration and no intravenous infusion infrastructure supplied with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. As an oral solid dosage form requiring no cold-chain handling, Lynparza 150 MG is stored and shipped below 30°C with standard pharmaceutical dry-goods logistics in original sealed packaging to protect tablets from moisture, substantially simplifying international shipment compared with refrigerated oncology biologics.

Ovarian cancer centers, breast oncology clinics, uro-oncology departments, hospital pharmacy departments, cancer research programs, distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries about Lynparza 150 MG Olaparib stock availability, current pricing, and international delivery timelines to their specific country. Buyers sourcing olaparib 150 mg tablets in China-market packaging for BRCA-mutated ovarian, breast, prostate, or pancreatic cancer maintenance treatment programs, establishing institutional PARP inhibitor procurement programs, or co-sourcing multiple oncology medicines in a single consolidated international shipment can browse the complete breast cancer medicines portfolio, ovarian cancer medicines portfolio, and prostate cancer medicines portfolio at Mediaid Pharmacy before submitting a consolidated quotation request.

Why Choose Lynparza 150 MG (Olaparib) from Mediaid Pharmacy?

Lynparza 150 MG Olaparib from Mediaid Pharmacy gives oncologists, gynecologic oncologists, breast oncologists, uro-oncologists, and oncology procurement teams access to the world’s first and most comprehensively approved PARP inhibitor an original molecule medicine by AstraZeneca that has established the clinical standard for BRCA-targeted synthetic lethality therapy across ovarian, breast, prostate, and pancreatic cancers. Olaparib’s proven OS benefit in two Phase 3 trials SOLO-1 (ovarian cancer; OS HR 0.55; p=0.0004) and OlympiA (early breast cancer; OS HR 0.68; p=0.009) its 7-year PFS rate of 46% versus 5% in BRCAm advanced ovarian cancer (SOLO-1 first-line maintenance), its 4-year iDFS benefit of 82.7% versus 75.4% in early high-risk breast cancer (OlympiA), its rPFS benefit in BRCAm mCRPC (PROfound; HR 0.34), and its first-line mCRPC activity with abiraterone (PROPEL; HR 0.66 overall) collectively establish olaparib 300 mg BID as the unambiguous PARP inhibitor backbone across four tumor types for patients with confirmed BRCA mutation status.

The 150 mg oral tablet format delivering the 300 mg BID standard dose as two tablets twice daily in China-market packaging (利普卓) without refrigeration, IV infusion, or reconstitution requirements enables home-based, patient-self-administered continuous PARP inhibition that is logistically compatible with global treatment programs, remote oncology centers, and international patient populations. Mediaid Pharmacy supplies Lynparza 150 MG Olaparib with full product documentation, specialist oncology supply support, and worldwide shipping from Dhaka. To source AstraZeneca companion oncology medicines including Tagrisso, Imfinzi, or Farxiga or a complete multi-indication oncology panel alongside Lynparza 150 MG, visit the Mediaid Pharmacy AstraZeneca medicines section and the oncology medicines portfolio, and contact the team for a personalized procurement quotation.

Frequently Asked Questions About Lynparza 150 MG (Olaparib)